Oral ANAVEX 2-73 regulatory update

Anavex said it is planning a double-blind, placebo-controlled Phase II/III trial of ANAVEX 2-73 to treat Alzheimer’s disease after receiving guidance from FDA. The aminotetrahydrofuran derivative agon...